Grant: Health System Impact Fellowships - Doctoral Central 1-year
McGill University
$35,000.00
Exploring the Real-World Value of Targeted Therapies in Lung Cancer
EF 2019-20
Résumé
I will be conducting my fellowship at the Institut national d'excellence en santé et en services sociaux (INESSS), which promotes clinical excellence and efficient use of resources in health and social services in Quebec. The Cancer Unit (CU) at INESSS, where I will be placed, provides timely evidence to Quebec's Ministry of Health and Social Services to support the improvement of clinical practice across the cancer-care continuum, and evaluates the value of innovations in cancer care, particularly the value of innovative therapies in the real-world context. The CU's current focus is in evaluating activities and generating real-world evidence in lung cancer, given its relatively high burden in Quebec. In-line with the CUs goals, my project will build a portrait on the use of targeted therapies (i.e. anti-EGFR drugs) as 1st-line treatment in advanced non-small cell lung cancer patients in Quebec, a crucial input to later evaluations of the real-world value of targeted therapies. The objectives of my projects are to use administrative data to 1) describe patient-, provider-, and institutional-level characteristics regarding the use of anti-EGFR drugs for 1st-line therapy, 2) create clinical endpoints that could be used to monitor patient outcomes after receiving anti-EGFR drugs for 1st-line therapy, and 3) develop methodologies to evaluate the real-world value of anti-EGFR drugs for 1st-line therapy. This project is a perfect blend of my interests and those of INESSS's in supporting the improvement of health services and evaluating innovations and interventions in cancer. The fellowship, combined with my doctoral studies, will provide me with a unique multifaceted training, mentorship, and networking experience to lead future work integrating academic and health care system perspectives for high-impact on the quality of life and health outcomes of those affected by cancer.
Programme
Health System Impact Fellowships - Doctoral Central 1-year
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
407508
Name
Qureshi Samia M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Fellowship : Health System Impact Fellowship Doctoral
Projecttitle
Exploring the Real-World Value of Targeted Therapies in Lung Cancer
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$35,000
Cihrequipment2
$0
Programname2
Health System Impact Fellowships - Doctoral Central 1-year
Keyworddelim
Cancer Control; Epidemiology; Health Care; Health Services Research; Lung Cancer; Policy Evaluation; Population Health; Public Health
Abstract
I will be conducting my fellowship at the Institut national d'excellence en santé et en services sociaux (INESSS), which promotes clinical excellence and efficient use of resources in health and social services in Quebec. The Cancer Unit (CU) at INESSS, where I will be placed, provides timely evidence to Quebec's Ministry of Health and Social Services to support the improvement of clinical practice across the cancer-care continuum, and evaluates the value of innovations in cancer care, particularly the value of innovative therapies in the real-world context. The CU's current focus is in evaluating activities and generating real-world evidence in lung cancer, given its relatively high burden in Quebec. In-line with the CUs goals, my project will build a portrait on the use of targeted therapies (i.e. anti-EGFR drugs) as 1st-line treatment in advanced non-small cell lung cancer patients in Quebec, a crucial input to later evaluations of the real-world value of targeted therapies. The objectives of my projects are to use administrative data to 1) describe patient-, provider-, and institutional-level characteristics regarding the use of anti-EGFR drugs for 1st-line therapy, 2) create clinical endpoints that could be used to monitor patient outcomes after receiving anti-EGFR drugs for 1st-line therapy, and 3) develop methodologies to evaluate the real-world value of anti-EGFR drugs for 1st-line therapy. This project is a perfect blend of my interests and those of INESSS's in supporting the improvement of health services and evaluating innovations and interventions in cancer. The fellowship, combined with my doctoral studies, will provide me with a unique multifaceted training, mentorship, and networking experience to lead future work integrating academic and health care system perspectives for high-impact on the quality of life and health outcomes of those affected by cancer.
Competitiondate
201904
Approvedterm2
1 yr 0 mth
Pinamesdelim
Qureshi, Samia M
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $35,000~ $0~